Melanie Cree, a pediatric endocrinologist and director of the University of Colorado Anschutz PCOS clinic, tells Yahoo
Data from this manuscript were published in abstract form in the proceedings of the 75th Annual Meeting of the American Diabetes Association, Boston, MA, USA, 59 June 2015
GLP-1 agonists could be the first effective treatment for OUD that does not act on the opioid receptor pathway
Yes, some people maintain their weight loss on a lower dose of Wegovy rather than the standard 2.4 mg
Molecular modification of peptide drug can be performed to improve their stability, extend their in vivo half-life and make them long-acting
GLP-1 receptor agonists like semaglutide and tirzepatide are not scheduled controlled substances, so the additional DEA telemedicine prescribing rules that apply to controlled substances don't apply here